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Abstract
Background: Although substance P (SP) is an important primary afferent modulator in nociceptive
processes, it is unclear whether SP regulates its own release from primary sensory neurons.
Results:  Using a highly sensitive radioimmunoassay for SP, we have demonstrated that the
activation of neurokinin-1 receptor by SP or GR73632 (a potent neurokinin-1 receptor agonist)
triggered an increase of SP release from cultured adult rat dorsal root ganglion (DRG) neurons
depending on the dose and exposure time within 60 min, and thereafter, the SP release level
gradually decreased over 360 min. Accompanying the SP release, a significant reduction in the
percentage of neurons expressing neurokinin-1 receptor on their membranes during exposure to
SP (200 pg/dish) occurred time dependently (56 ± 5% and 32 ± 2% at 180 and 360 min,
respectively). The GR73632-evoked (10 nM, 60 min) SP release was attenuated by several
inhibitors for mitogen-activated protein kinase kinase, p38 mitogen-activated protein (MAP) kinase
and cyclooxygenase-2 (COX-2), protein kinase C (PKC), respectively. In contrast, a c-Jun NH2-
terminal kinase inhibitor increased the GR73632-evoked SP release.
Conclusion: These results indicate that the neurokinin-1 receptor activation by its agonists
regulates the SP release process involving the activation of MAP kinases, PKCs and COX-2 from
cultured DRG neurons.
Background
Substance P (SP) is one member of the tachykinin
neuropeptide family that shares a carboxy-terminal
sequence Phe-X-Gly-Leu-Met-NH2 [1], along with neuroki-
nin A, neurokinin B and neuropeptide K, neuropeptide-γ.
SP is derived from the preprotachykinin-A gene, and is syn-
thesized in the dorsal root ganglion (DRG) neurons [2].
SP is released through a very complex process involving
some important intracellular effectors, such as extracellular
calcium influx, 1,4,5-inositol trisphosphate-induced cal-
cium release, the activation of extracellular signal-regulated
kinase (ERK), cyclooxygenases (COXs) and prostagland-
ins, and the cyclic AMP-dependent protein kinase A (PKA)
from primary afferent neurons to convey information
about various noxious stimuli [3-6]. Previous studies have
demonstrated that SP functions as an important
Published: 25 December 2007
Molecular Pain 2007, 3:42 doi:10.1186/1744-8069-3-42
Received: 23 August 2007
Accepted: 25 December 2007
This article is available from: http://www.molecularpain.com/content/3/1/42
© 2007 Tang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Pain 2007, 3:42 http://www.molecularpain.com/content/3/1/42
Page 2 of 10
(page number not for citation purposes)
neurotransmitter and/or, as a primary afferent modulator
in nociceptive processes, thereby potentiating excitatory
input to nociceptive neurons [7-10].
The biological effects of SP are mediated through binding
to the specific G-protein-coupled neurokinin receptors
designated neurokinin-1, -2 and -3 receptors [11]. Once
activated by SP, the neurokinin receptor induces the acti-
vation of several second messenger systems, such as phos-
pholipase C (PLC) and adenylate cyclase, thereby
increasing the consequent production of 1,4,5-inositol tri-
sphosphate and cyclic AMP [12]. Moreover SP has been
shown to induce the activation of ERK1/2 and p38
mitogen-activated protein (MAP) kinases, nuclear factor-
kappa B and protein kinase C (PKC), and thereafter to
increase the production of prostaglandin E2  and the
expression of COX-2 [13-15]. Interestingly, both anatom-
ical and functional evidence have also suggested that neu-
rokinin-1 receptors may function as auto-receptors in
DRG neurons [16,17]. In view of the above-mentioned
observations on the release and the biological effects of
SP, it is considered important to clarify whether the
release of SP is induced via the activation of neurokinin-1
receptor, while also elucidating what type of signaling can
occur in the process of SP release via the neurokinin-1
receptor from cultured adult rat DRG neurons. Hence, the
objective of the present study is designed to demonstrate
whether the release of SP may be stimulated by itself
through the activation of its receptors and the involve-
ment of some important intracellular effectors (such as
MAP kinase, PLC and PKC, COX and PKA) from cultured
DRG neurons.
Results
The release of SP induced by itself from cultured rat DRG 
neurons
To investigate whether SP induces its own release from
cultured DRG neurons, we examined the effects of SP on
the release of SP in a dose- and time-dependent manner.
Based on the amount of the SP release induced by various
chemicals in our previous study [5,6,18], we selected 200
pg/dish of SP as an appropriate concentration for our
experimental conditions for investigating the possibility
of self-induced SP release. A time-course of SP release
induced by SP (200 pg/dish) from cultured DRG neurons
is shown in Fig. 1A. As a peak of SP release was observed
after the 60 min incubation, we decided to use the 60 min
incubation with SP (200 pg/dish) as an experimental con-
dition for examining various drugs on the self-induced SP
release. As shown in Fig. 1B, SP evoked a dose-dependent
release of SP during a 60 min incubation of cultured DRG
neurons.
It is well known that all three neurokinin receptors
(neurokinin-1, -2 and -3 receptors) are expressed in DRG
neurons. We therefore investigated whether neurokinin-1
and/or other neurokinin receptor(s) are involved in the
SP release induced by itself. The increase in the SP release
evoked by itself was partially significantly attenuated by 1
μM CP-96,345 (a selective antagonist of neurokinin-1
receptor) [19] and by 100 nM GR94800 (a selective antag-
onist of neurokinin-2 receptor) [20], not by 1 μM
SB222200 (a selective antagonist of neurokinin-3 recep-
tor) [20] as shown in Fig. 1C, whereas these antagonists
did not have any effect when used alone (Data not
The SP release induced by itself from cultured adult rat DRG  neurons Figure 1
The SP release induced by itself from cultured adult 
rat DRG neurons. Time-dependent (A) and dose-depend-
ent (B) effects of SP on its own release from cultured DRG 
neurons. (C) Effects of neurokinin receptor antagonists (1 
μM CP-96,345, 1 μM SB222200 and 100 nM GR94800) on 
the SP release from cultured DRG neurons exposed to SP. 
The data are expressed as means ± S.E.M. (bars) from 3–5 
(A), 4 (B) or 3 (C) separate experiments. *, ** and *** denote 
p < 0.05, 0.01 and 0.001, respectively.
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shown). Based on the results shown in Fig. 1C, both the
neurokinin-1 and -2 receptors seem to be involved in the
process of SP release, however, the detailed pharmacolog-
ical action(s) of the neurokinin-2 receptor in the sub-
stance P release will be examined in future experiments.
Immunocytochemical localization of the neurokinin-1 
receptor and SP
We next investigated the time-dependent changes in the
expression of SP and its neurokinin-1 receptor in cultured
DRG cells incubated in serum-free DMEM (containing
peptidase inhibitors) with or without SP (200 pg/dish) in
the presence/absence of 1 μM CP-96,345. The specific
type of cells indicated by arrows in Figs 2A and 2B can eas-
ily be identified to be DRG neurons by the morphology
(characteristic phase bright cell bodies bearing either bi-
or multi-polar neurites observed by using the Olympus
IX71 inverted microscope with a 20X Ph1 objective) and
by the Schwann cell marker S100 (Rabbit anti-cow S100;
1:1,000 dilution; Dako, Glostrup, Denmark)- and the
astrocyte marker GFAP (Mouse anti-glial fibrillary
acidic protein; 1:800 dilution; Chemicon, Temecula, CA)-
negative expression (Data not shown). As shown in
Figs 2Ai–iv, the neurokinin-1 receptors were distributed
on the membrane and in the cytoplasm of smaller DRG
neurons in a naive state. The ratio of the number of neu-
rons expressing the neurokinin-1 receptor on their mem-
branes to the total number of neurokinin-1 receptor-
positive neurons in a randomly selected field in each
image from three separate experiments was simultane-
ously calculated. The percentage of neurons expressing
neurokinin-1 receptor on their membrane in a naive state
was 91 ± 5%, 82 ± 4% and 74 ± 4%, 71 ± 3% in Figs 2Ai–
iv, respectively. Interestingly, a significant reduction in the
percentage of neurons expressing neurokinin-1 receptor
on their membranes was observed after the time-depend-
ent stimulation of 200 pg/dish SP (85 ± 4%, 71 ± 7% and
56 ± 5%, 32 ± 2% in Figs 2Av–viii, respectively) in com-
parison to their respective controls (p > 0.05, p > 0.05 and
p < 0.05, p < 0.001, respectively). Furthermore, the reduc-
tion induced by SP was attenuated by the pretreatment
(10 min) with 1 μM CP-96,345 (86 ± 4%, 85 ± 7% and 84
± 2%, 84 ± 5% in Figs 2Aix–xii, respectively). On the other
hand, we observed the SP content to be mainly distributed
in the cytoplasm of the smaller DRG neurons (Fig. 2B).
The long-term (60 to 360 min) exposure of the DRG neu-
rons to SP (200 pg/dish) thus resulted in a reduction of
the SP content in their cytoplasm (Figs 2Bv–viii), whereas
the pretreatment with 1 μM CP-96,345 blocked the reduc-
tion of the SP content (Figs 2Bix–xii). The SP-evoked
expression change of the neurokinin-1 receptor from the
membrane to the intracellular compartment in somas of
DRG neurons should therefore be considered as the recep-
tor internalization (a pharmacologically specific index of
neurokinin-1 receptor-SP interaction).
The SP-induced changes of neurokinin-1 receptor 
expression in the cytosolic and membrane fractions
Based on the neurokinin-1 receptor localization results
shown in Fig. 2A, we attempted to further quantify the lev-
els of neurokinin-1 receptor in the cytosolic and mem-
brane fractions of cultured DRG neurons. As shown in
The immunocytochemical localization of the neurokinin-1  receptor and SP in cultured adult rat DRG cells Figure 2
The immunocytochemical localization of the neurok-
inin-1 receptor and SP in cultured adult rat DRG 
cells. The time-dependent expression of the neurokinin-1 
receptor (A) and SP (B) in cultured DRG neurons divided 
into three groups: control group (i-iv), 200 pg/dish SP group 
(v-viii) and 200 pg/dish SP plus 1 μM CP-96,345 group (ix-xii). 
Photomicrographs were taken with the Olympus IX71 
inverted microscope (x40). The arrows indicate the neuroki-
nin-1 receptor- or SP-positive neurons (brown). The red 
arrows indicate the DRG neurons where the neurokinin-1 
receptors are not expressed in their membrane. Scale bars: 
20 μm.
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Figs 3A and 3B, the time-dependent (10–360 min)
exposure of cultured DRG neurons to SP (200 pg/dish)
resulted in a significant decrease of the neurokinin-1
receptor expression in the membrane fractions (104 ±
15%, 74 ± 4% and 42 ± 5%, 14 ± 1% in Figs 3A and 3B,
respectively, compared with the control at 10 min). The
SP-induced decrease of that was completely blocked by
the 10 min pretreatment with 1 μM CP-96,345 (102 ± 9%,
100 ± 7% and 74 ± 11%, 61 ± 14% in Figs 3A and 3B,
respectively, compared with the control at 10 min). There-
fore the activation of neurokinin-1 receptor by SP is
accompanied by the internalization of its receptors, how-
ever, we could not identify the proteins detected by anti-
substance P receptor antibody in the cytosol as a func-
tional neurokinin-1 receptor. Interestingly, we observed a
gradual decrease of the neurokinin-1 receptor expression
in the membrane fraction from the untreated DRG neu-
rons (the control). These data suggest the endogenous SP
released from the DRG neurons could enhance the turno-
ver of neurokinin-1 receptor from the membrane to the
cytosol as the released SP is not taken into the DRG cells.
However, after the induction of internalization by the
stimulation of SP, the level of the cytosolic proteins
detected by anti-substance P receptor antibody does not
change, thus suggesting a part of internalized neurokinin-
1 receptor protein could be degraded to maintain the
amount of neurokinin-1 receptor to some extent within
the cytosol.
Characteristics of the GR73632-induced release of SP
The data shown in Figs 1C and 2 indicate that the activa-
tion of neurokinin-1 receptor is involved in the SP release
induced by SP. We therefore selected another potent neu-
rokinin-1 receptor agonist GR73632 (showing no cross-
reactivity with anti-SP serum in radioimmunoassay) to fur-
ther investigate the molecular mechanisms of the SP
release via the activation of the neurokinin-1 receptor in
cultured DRG neurons. As shown in Fig. 4A, it was
observed that a 60 min incubation with GR73632 (1–100
nM) stimulated a significant increase in the SP release in a
dose-dependent manner from the cultured DRG neurons.
The increases in the SP release induced by GR73632 at var-
ious concentrations were almost completely blocked by
the 10 min pretreatment with CP-96,345. Based on the
results shown in Fig. 4B, we thought that the 60 min incu-
bation with 10 nM GR73632 was an appropriate condi-
tion in our experiments. However, we observed that a
time-dependent treatment (10 min to 24 h) of GR73632
(10 nM) did not cause any detectable change in the total
amount of SP content from cultured DRG neurons and the
culture medium (Fig. 4C). In addition, significant changes
of the preprotachykinin mRNA expression were not caused
by the time-dependent (10–360 min) exposure of cultured
DRG neurons to 10 nM GR73632 (Data not shown).
Therefore, the effect of GR73632 under our experimental
conditions should not be considered to cause a rapid
increase in the synthesis of the SP content in cultured DRG
neurons.
Whether the complex process of SP release induced by
GR73632 requires the activation of MAP kinases, COXs,
PLC or PKCs, PKA in cultured DRG neurons, still remains
Time-course studies of the SP-induced neurokinin-1 recep- tor expression in the cytosolic and membrane fractions from  cultured adult rat DRG neurons Figure 3
Time-course studies of the SP-induced neurokinin-1 
receptor expression in the cytosolic and membrane 
fractions from cultured adult rat DRG neurons. (A) 
Representative blots of the neurokinin-1 receptor expres-
sion in the cytosolic and membrane fractions from cultured 
DRG neurons exposed to SP for 10 to 360 min. All data have 
been quantified by normalizing the neurokinin-1 receptor 
expression level of control in the membrane (B) or cytosolic 
(C) fraction at 10 min, respectively. The data are expressed 
as the means ± S.E.M. (bars) from 3 separate experiments. # 
denotes a p < 0.05 as compared to the effect of untreated 
control at 10 min, *p < 0.05 and **p < 0.01 versus the effect 
of the untreated control at the same time by a one-way 
analysis of variance followed by Bonferroni's test.
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to be elucidated. As shown in Fig. 5A, both U0126 and
SB203580 exhibited a significant inhibitory effect on the
SP release evoked by GR73632, whereas SP600125 stimu-
lated an increase in the SP release. When these three
inhibitors [6] of MAP kinases were used alone, only a c-
Jun NH2-terminal kinase (JNK) inhibitor SP600125 had a
weak tendency to increase the SP release (Fig. 5A). We also
observed that the GR73632-induced SP release (Figs 5B
and 5D) was significantly attenuated by NS-398 (a highly
selective inhibitor of COX-2) [5], indomethacin (a non-
selective inhibitor of COX1/2) [6] or by PKCε transloca-
tion inhibitor peptide [21], Gö6976 (a selective inhibitor
for PKCα-, βI-isozymes) [22] or bisindolylmaleimide I (a
broad inhibitor for PKCα-, βI-, βII-, γ-, δ-, ε-isozymes)
[22]. However, neither U73122 (a selective inhibitor of
PLC) [23] nor H89 (a selective inhibitor of PKA) [4] influ-
enced the SP release induced by GR73632 (Figs 5C and
5D).
Up-regulation of COX-2 expression induced by SP and by 
GR73632
To clarify the possible signal transduction pathway(s)
involved in the SP release via the activation of neurokinin-
1 receptor, the activation status of COX-2 was assessed
using specific antibodies for COX-2 after the stimulation
of SP or GR73632 in the absence or presence of various
inhibitors. The time-dependent exposure of DRG neurons
to SP (200 pg/dish) resulted in the significant increase of
de novo protein synthesis of COX-2 (Fig. 6A). The 60 min
incubation with 10 nM GR73632 also up-regulated the
expression of COX-2 protein (Fig. 6B), whereas the
increase in the expression of COX-2 protein evoked by
GR73632 was significantly attenuated by the pretreatment
with CP-96,345, U0126, NS-398 or three inhibitors for
PKC isozymes (Gö6976, bisindolylmaleimide I and PKCε
translocation inhibitor peptide), respectively. However,
neither SB203580 nor SP600125 influenced the up-regu-
lation of COX-2 expression induced by GR73632.
Discussion
In the present study, we demonstrated for the first time
that the activation of neurokinin-1 receptor by its agonists
(SP or GR73632) modulates the SP release from cultured
DRG neurons through some important intracellular
effectors.
During the 360 min exposure of DRG to SP (200 pg/dish),
a peak response in the SP release was observed within the
first 60 min, whereas a gradual decrease in the SP release
level was obtained at later time points (180 and 360 min)
(Fig. 1A). The release pattern of SP induced by itself may
be explained by the internalization and recycling of the
neurokinin-1 receptor [24], because the immunocyto-
chemical and Western blotting results (Figs 2A and 3)
showed the existence of neurokinin-1 receptor internali-
zation induced by SP, and it also indicated an inhibitory
effect of the continuous exposure to SP on the neurokinin-
1 receptor recycling. In addition, the time-dependent
reduction in SP content of the DRG neurons exposed to SP
provides an explanation for the existence of SP release
(Fig. 2B). Our present findings are therefore in agreement
with the hypothesis that SP induces its own release via
its auto-receptor, the neurokinin-1 receptor [16,17]. Our
Effects of GR73632 on the release and total content of SP  from cultured adult rat DRG neurons Figure 4
Effects of GR73632 on the release and total content 
of SP from cultured adult rat DRG neurons. Dose-
dependent (A) and time-dependent (B) effects of GR73632 
on the release of SP from cultured adult rat DRG neurons. 
(C) Total SP content from cultured DRG neurons and the 
culture medium. The data are expressed as means ± S.E.M. 
(bars) from 3–4 (A), 4 (B) or 3 (C) separate experiments. * 
and ** denote p < 0.05 and 0.01, respectively.
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data also indicated that SP may function as a
neuromodulator in the slow release response itself from
cultured DRG neurons. The precise mechanism of the
association between the SP release and the neurokinin-1
receptor internalization should be revealed by further
studies.
The neurokinin-1 receptor has a preferential affinity for SP
[25]. The expression of the neurokinin-1 receptor is
observed mainly in the small rat DRG neurons by in situ
hybridization [26]. We have therefore focused our atten-
tion on the involvement of the neurokinin-1 receptor in
the SP release from cultured DRG neurons. GR73632 (a
selective agonist of the neurokinin-1 receptor) stimulated
a significant increase in the release of SP via acting on the
neurokinin-1 receptor. To clarify the characteristics of SP
release via the neurokinin-1 receptor, we further investi-
gated the possible involvement of several intracellular
effectors, such as MAPKs, COX-2 and PLC, PKA and PKCs.
The MAPKs family contains at least three protein kinases
in series: JNK, p38 MAP kinase and MEK (a kinase imme-
diately upstream of ERK that phosphorylates the tyrosine
and threonine residues on ERK1/2 required for activa-
tion). They are often involved in the intracellular trans-
mission of extracellular signals [27]. In our previous
study, the activation of ERK1/2 was demonstrated to be
involved in the SP release evoked by bradykinin [6]. Fie-
bich et al. [13] and Yang et al. [28] also indicated that
ERK1/2 and p38 MAP kinase can be rapidly activated by
SP in a dose-dependent manner. In view of the above-
mentioned observations and the results shown in Fig. 5A,
p38 MAP kinase and MEK seem to play a role in increasing
the release of SP. In contrast, the data shown in Fig. 5A
suggest that the JNK is likely to be associated with the sup-
pression of SP release from cultured DRG neurons,
although this kinase was reported to function as an
important factor involved in SP-stimulated secretion and
production of inflammatory mediators in rat peritoneal
mast cells [29].
It is well known that the binding of the ligand to the neu-
rokinin-1 receptor activates several second messenger sys-
tems, including 1,4,5-inositol trisphosphate formation
via PLC activation and cyclic AMP accumulation via ade-
nylate cyclase [12]. The activation of cyclic AMP-depend-
ent PKA was also reported to be involved in the SP release
caused by prostaglandin E2[30]. However, we observed
that PLC and PKA did not influence the SP release via the
neurokinin-1 receptor from cultured DRG neurons.
PKC is a family of serine- and threonine-specific protein
kinases, which has been suggested to function as an
important intracellular signaling molecule in primary
afferent nociceptors, while also being implicated in acute
Characteristics of the GR73632-evoked SP release from cul- tured adult rat DRG neurons Figure 5
Characteristics of the GR73632-evoked SP release 
from cultured adult rat DRG neurons. Some cells were 
left untreated as a control, all other cells were treated with 
GR73632 alone or together with three MAP kinases cascades 
inhibitors (10 μM U0126, 15 μM SB203580 and 30 μM 
SP600125), PLC inhibitor (10 μM U73122) or with COX 
inhibitors (1 μM NS-398 and 1 μM indomethacin), PKC inhib-
itors (1 μM Gö6976, 1 μM bisindolymaleimide, 200 μM PKCε 
translocation inhibitor peptide) or with PKA inhibitor (10 μM 
H89) in DMEM (serum free) for 60 min. The data are 
expressed as the means ± S.E.M. (bars) from 3–5 (A), 6 (B) 
or 4 (C), 4 (D) separate experiments. *, ** and *** denote p 
< 0.05, 0.01 and 0.001, respectively.
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and chronic inflammatory as well as neuropathic pain.
The activation of PKC was also reported to induce the
synthesis of COX-2 and the release of prostaglandin E2 in
primary midbrain astrocytes [31]. Previous study in our
laboratory [32] has shown that the time-dependent and
transient induction of COX-2 mRNA was observed 30 min
after bradykinin (a potent pro-inflammatory mediator)
stimulation in cultured DRG neurons. The short-term
exposure of the DRG neurons to bradykinin at 1 μM for 30
min also induced small but significant amounts of pros-
taglandin E2  release depending on the activation of
COX1/2. Our present findings also demonstrated a signif-
icant increase in COX-2 expression stimulated during a 60
min exposure of cultured DRG neurons to SP (Fig. 6A).
Moreover, the de novo protein synthesis of COX-2
requires the activation of PKCs and MEK (Fig. 6B). In view
of the above-mentioned observations and results shown
in Figs 5D and 6, it is suggested that PKC isozymes includ-
ing ε type play the important roles in the de novo protein
synthesis of COX-2 via the neurokinin-1 receptor, and
thereby increase the SP release from cultured DRG
neurons.
Interestingly, our results in the present work are partially
consistent with several previous observations in vivo. For
example, the activation of neurokinin-1 receptors by
intrathecal injection of SP evokes thermal hyperalgesia
and spinal prostaglandin E2 release which can be reversed
by spinal COX-2 inhibition and by the intrathecal delivery
of the p38 MAP kinase inhibitor SB203580; spinal PKC
inhibition blocks the intrathecal injection of SP-mediated
thermal hyperalgesia [34-37]. Moreover, the inhibition of
PLC-β and PKC-ε can completely block both the neuroki-
nin-1 receptor agonist-induced TRPV1 (transient receptor
potential vanilloid subtype 1) potentiation and heat
hyperalgesia [38]. Similar to the observation reported by
Zhang et al. [38], we also observed that the activation of
neurokinin-1 receptor by its agonist GR73632 to enhance
the capsaicin-evoked substance P release in our latest
research, which thus demonstrated that the potentiation
of capsaicin-evoked substance P release by GR73632 via
the activation of neurokinin-1 receptor depends on the
activation of PKCs, MEK and p38 MAP kinase, PLC and
COXs from cultured DRG neurons (Unpublished data).
However, the detailed relationships among the activation
of PLC, PKC, MAP kinases and COXs regarding the
enhancement of capsaicin-evoked substance P release by
GR73632 via the activation of neurokinin-1 receptor will
be described in a study to be published in the not-so-dis-
tant future. Based on our findings and the above-men-
tioned observations reported previously, we proposed a
possible molecular mechanism underlying the SP release
induced by the neurokinin-1 receptor agonists (SP and
GR73632) from cultured rat DRG neurons. The long-term
exposure of DRG neurons to SP or GR73632 resulted in
the activation of MEK, p38 MAP kinase and PKC at an
early stage and thereafter induced the synthesis of COX-2,
which they contribute to the SP release triggered by the
neurokinin-1 receptor.
Conclusion
This study demonstrated that the activation of neuroki-
nin-1 receptor by its agonists (SP and GR73632) regulates
the SP release process depending on the activation of
Effects of SP and GR73632 on COX-2 protein expression in  cultured adult rat DRG neurons Figure 6
Effects of SP and GR73632 on COX-2 protein expres-
sion in cultured adult rat DRG neurons. (A) The time-
dependence of COX-2 expression in cultured DRG neurons 
exposed to SP. (B) The protein levels of COX-2 in DRG neu-
rons treated with GR73632, either alone or together with 1 
μM CP-96,345, three MAP kinases cascades inhibitors (10 
μM U0126, 15 μM SB203580 and 30 μM SP600125) or with 1 
μM NS-398, PKC inhibitors (1 μM Gö6976, 1 μM bisindoly-
maleimide, 200 μM PKCε translocation inhibitor peptide) for 
60 min were measured by Western blot analysis. All data 
have been normalized to the COX-2 expression level of con-
trol group. The data are expressed as the means ± S.E.M. 
(bars) from 4 (A) or 4 (B) separate experiments. *, ** and *** 
denote p < 0.05, 0.01 and 0.001, respectively.
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MEK, p38 MAP kinase and PKC, and the de novo protein
synthesis of COX-2, while also indicating that the JNK
likely has an inhibitory effect on the SP release. These
observations provide important evidence to help us
understand the molecular mechanisms of inflammatory
pain modulated by SP in primary afferent neurons.
Methods
Isolation and culture of rat DRG cells
According to a previously described method [5,6,23],
DRGs of young adult Wistar rats (6–9 weeks of age) were
dissociated into single isolated neurons and non-neuro-
nal cells by the treatment of collagenase (Sigma, St. Louis,
MO, USA) and trypsin (Invitrogen, Burlington, ON, Can-
ada). The cells (3 DRGs/dish) were maintained at 37°C in
a water-saturated atmosphere with 5% CO2 for 5 days
before the initiation of the experiments. All procedures for
animal experiments were performed according to the
Guide for Animal Experimentation, Hiroshima Univer-
sity, and the Committee of Research Facilities for Labora-
tory Animal Sciences, Graduate School of Biomedical
Sciences, Hiroshima University, Japan.
Measurement of SP content in the culture medium and in 
the cultured rat DRG neurons
Except for some cultured cells treated by peptidase inhib-
itors containing 1 μM phosphoramidon (Sigma), 4 μg/ml
bacitracin (Sigma) and 1 μM captopril (Sigma) alone (as
a control), other cultured cells were exposed to SP (Pep-
tide Institute, Osaka, Japan) or to GR73632 (Sigma),
either alone or together with various inhibitors such as
Gö6976 (Calbiochem, Darmstadt, Germany), PKCε trans-
location inhibitor peptide (Calbiochem) and bisindolyl-
maleimide I (Calbiochem), indomethacin (Sigma) and
SB222200 (Sigma), GR94800 (Sigma) and U73122
(Sigma), SP600125 (Sigma) and H89 (Seikagaku, Tokyo,
Japan) in 1 ml serum-free DMEM (Nissui, Tokyo, Japan)
containing peptidase inhibitors for a designated period of
time at 37°C in a water-saturated atmosphere with 5%
CO2. Thereafter, the SP content collected from the culture
medium and the cultured DRG neurons was measured by
a highly sensitive radioimmunoassay [5,18], respectively.
For examining the amount of SP-induced SP release in the
present experiments, we developed a new computational
method. Briefly, SP at a specified concentration (100, 200
and 800, 1,000 pg/dish) was used to stimulate two groups
of cultured DRG neurons in both the absence and pres-
ence of various antagonists for three neurokinin receptors
(neurokinin-1, -2 and -3 receptors). The SP content was
immediately collected from the culture medium (1 ml)
after the SP stimulation for the first group, and the
amount of SP content was examined from the culture
medium (1 ml) after the SP stimulation lasted for 10, 60,
180, 360 minutes, respectively, for the second group. The
numerical difference in the SP content between the two
groups is considered to be the amount of SP release
induced by this specified concentration of SP during a
specific time period from cultured DRG neurons.
Immunocytochemical staining for the neurokinin-1 
receptor and SP in the cultured rat DRG neurons
Immunocytochemical staining for the neurokinin-1
receptor and SP in cultured DRG neurons on coverglasses
was performed with a standard immunoperoxidase tech-
nique [Histofine Simple Stain Rat MAX-PO (MULTI) kit;
Nichirei, Tokyo, Japan] according to the manufacturer's
instructions. Briefly, 4% paraformaldehyde-fixed cultured
DRG cells on coverglasses were incubated with anti-neu-
rokinin-1 receptor (1:2,000 dilution; Sigma) or anti-SP
serum (1:1,000 dilution; a gift of Dr. J.S. Hong, National
Institute of Environmental Health Sciences, NIH, USA)
[33]. After the treatment with Histofine simple stain rat
MAX-PO (MULTI), color development (brown) was per-
formed using a DAB substrate kit (Nichirei), and the cov-
erglasses were counterstained with hematoxylin (blue).
According to the manufacturer's instructions for the
datasheet of anti-substance P receptor antibody (S8305,
Sigma), it is guaranteed that the antibody specifically rec-
ognizes the neurokinin-1 receptor peptide (rat, amino
acids 393–407) in immunoblotting. Immunocytochemi-
cal controls demonstrating antibody specificity for the
neurokinin-1 receptor and SP included immunostaining
cultured cells on coverglasses, but the primary antibody
was omitted. The omission of the primary antibody
resulted in no staining in the cells.
Subcellular fractionation
After a 10 min pretreatment with the presence or absence
of 1 μM CP-96,345 (Pfizer, Groton, CT, USA), the cul-
tured DRG cells were incubated in serum-free DMEM
(containing peptidase inhibitors) with or without SP (200
pg/dish) for 10, 60, 180, 360 minutes, respectively. The
isolation of cytosolic and membrane fractions from these
DRG cells was performed with a standard cell compart-
ment kit fractionation procedure (Cell compartment kit;
Qiagen, Tokyo, Japan) according to the manufacturer's
instructions. Protein concentrations were determined,
and then the neurokinin-1 receptor levels in the same
amounts of cytosolic and membrane proteins were ana-
lyzed separately by a Western blot analysis.
Western blot analysis
At the end of the SP release experiments, the cell samples
were processed for Western blot analysis as previously
described [6]. Primary antibodies were raised against
COX-2 (1:1,000 dilution; COX-2 polyclonal antibody;
Cayman Chemical, Ann Arbor, MI), β-actin (1:5,000 dilu-
tion; the mouse monoclonal antibody for β-actin; Sigma)
or anti-substance P receptor (1:2,000 dilution; Sigma).
The horseradish peroxidase-conjugated anti-rabbit andMolecular Pain 2007, 3:42 http://www.molecularpain.com/content/3/1/42
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anti-mouse secondary antibodies (1:2,000 dilution;
Cell Signaling Technology, Beverly, MA) were used for
chemiluminescence detection according to the manufac-
turer's instructions, respectively.
Statistical analysis
The data are presented as the mean ± S.E.M. Statistical
analyses were performed using a one-way ANOVA fol-
lowed by Bonferroni's test. P values less than 0.05 were
considered significant.
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